GURU.Markets stock price, segment price, and overall market index valuation
The company's share price DBV Technologies S.A.
DBV Technologies is a French biotech company developing a patch for the treatment of food allergies. Its stock price is the story of a long and difficult battle to gain FDA approval, leading to significant volatility and investor disappointment.
Share prices of companies in the market segment - Pharma skin
DBV Technologies (DBVT) is a French biopharmaceutical company developing the Viaskin epicutaneous immunotherapy platform for the treatment of food allergies, primarily peanut allergies. We classify it in the Pharmaceuticals/Skin segment. The chart below shows the dynamics of the allergy treatment sector.
Broad Market Index - GURU.Markets
DBV Technologies is a French biopharmaceutical company developing epicutaneous immunotherapy (patches) for the treatment of food allergies, particularly to peanuts. Its innovative approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how DBV compares to it.
Change in the price of a company, segment, and market as a whole per day
DBVT - Daily change in the company's share price DBV Technologies S.A.
Shares of DBV, a French biopharmaceutical company, are experiencing extreme volatility. Change_co measures the market reaction to news about its peanut allergy patch and regulatory decisions. This metric is an important component of formulas on System.GURU.Markets that assess biotech risks.
Daily change in the price of a set of shares in a market segment - Pharma skin
DBV Technologies S.A. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with DBVT, which focuses on food allergy treatments, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
DBV is a French biopharmaceutical company developing a patch for the treatment of food allergies. Its history exemplifies the extreme volatility and risk in biotech. The chart below illustrates general market fluctuations, making DBV's drama particularly instructive.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization DBV Technologies S.A.
DBV Technologies's annual performance is a multi-year story about its efforts to gain FDA approval for its peanut allergy patch. Its market cap fluctuates dramatically over the course of 12 months based on news about its interactions with the regulator. A successful outcome could open up a huge market and fundamentally change the company's fortunes.
Annual dynamics of market capitalization of the market segment - Pharma skin
DBV Technologies S.A. is a French biotech company developing epicutaneous immunotherapy (patches) for the treatment of food allergies. Its stock price is extremely volatile, reflecting its long and challenging path to regulatory approval for its innovative product.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
DBV Technologies is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its share price (ADR) reflects investor hopes for the success of its innovative allergy patch trials. The company's chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization DBV Technologies S.A.
The dynamics of DBV, a biopharmaceutical company, are speculative. The monthly fluctuations on the chart reflect not revenue, but news about the company's interactions with the FDA regarding its peanut allergy patch, the approval of which determines its entire future value.
Monthly dynamics of market capitalization of the market segment - Pharma skin
Developing treatments for food allergies is a complex area of biotechnology with a long history of regulatory hurdles. The dynamics of this sector, shown in the chart, reflect these challenges. In this challenging environment, companies like DBV Technologies continue their research.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
DBV Technologies, a French biopharmaceutical company developing a food allergy patch, has a highly volatile history. Its shares move solely on regulatory news, completely ignoring overall market trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization DBV Technologies S.A.
Shares of DBV Technologies, which is developing a food allergy patch, are extremely news-sensitive. Weekly price movements depend entirely on clinical trial results and regulatory decisions, particularly from the FDA in the US. The chart below illustrates how investors' hopes and disappointments in biotech drive sharp price fluctuations.
Weekly dynamics of market capitalization of the market segment - Pharma skin
How unique is DBV Technologies' performance in the biotech sector? This chart compares the company's weekly stock price movements, driven by news of its allergy patch, with the overall trend. This helps us understand whether its sharp move is a unique response to regulatory decisions or reflects broader sentiment across the volatile sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
DBV Technologies is developing a patch for treating food allergies. Like many biotechs, its fate depends on regulatory decisions. This chart shows how disconnected its weekly performance is from the market. Share movements are driven by news about clinical trials, not the overall economic situation.
Market capitalization of the company, segment and market as a whole
DBVT - Market capitalization of the company DBV Technologies S.A.
The DBV Technologies price chart is a dramatic tale of hope and disappointment in biotech. The company's market capitalization, developing a peanut allergy patch, has risen and fallen depending on the decisions of US regulators. This dynamic vividly illustrates how an FDA verdict can determine the fate of years of research.
DBVT - Share of the company's market capitalization DBV Technologies S.A. within the market segment - Pharma skin
DBV Technologies S.A. is aiming to capture market share in food allergy treatments with its unique epicutaneous immunotherapy patch technology. Its market capitalization reflects both the long and challenging path to product approval and its enormous potential.
Market capitalization of the market segment - Pharma skin
The chart below is a barometer of the biotech segment focused on allergy treatments. DBV Technologies, with its innovative Viaskin platform, is a prominent player. The fluctuations in the chart reflect the overall risks and expectations associated with regulatory decisions for this entire class of drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
This chart visualizes hope for millions of people with food allergies. DBV Technologies' market cap reflects investors' faith in its innovative immunotherapy patch. The line's dynamics demonstrate how a single breakthrough idea in medicine can create enormous value and capture a significant share of the global pharmaceutical industry.
Book value capitalization of the company, segment and market as a whole
DBVT - Book value capitalization of the company DBV Technologies S.A.
DBV Technologies' book value represents its scientific and technological capital. The chart below reflects the valuation of its patents for the Viaskin™ epicutaneous immunotherapy platform and its manufacturing equipment. The dynamics illustrate the company's investment in developing non-invasive treatments for food allergies.
DBVT - Share of the company's book capitalization DBV Technologies S.A. within the market segment - Pharma skin
For DBV Technologies, which develops allergy patches, its tangible assets are not massive chemical plants, but specialized laboratories and production lines for creating innovative products. The chart shows the company's share of this high-tech pharmaceutical infrastructure.
Market segment balance sheet capitalization - Pharma skin
Below you can see the overall book value of the pharmaceutical sector. Compared to this, DBV Technologies, which is developing a food allergy patch, looks like a "lightweight." Its value lies in its unique technology and patents, not its gigantic manufacturing facilities. Its modest book value is typical for a biotech company focused on R&D.
Book value of all companies included in the broad market index - GURU.Markets
DBV Technologies is developing epicutaneous immunotherapy, a "patch" for food allergies. The company's assets are not factories, but clinical data and patents for this revolutionary technology. Their balance sheet represents the value of a scientific breakthrough. Against the backdrop of the entire material world, the chart below demonstrates how knowledge can become the most valuable asset.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - DBV Technologies S.A.
DBV Technologies' balance sheet represents its cash reserves. Its market capitalization represents the fading faith in its peanut allergy patch after several failed trials. The MvsBCap_Co chart, close to one, shows that the market values the company at only slightly more than the cash in its coffers, writing off the "dream" as a distant memory.
Market to book capitalization ratio in a market segment - Pharma skin
DBV Technologies is developing epicutaneous immunotherapy, specifically a peanut allergy patch. Its valuation is based almost entirely on the potential of this technology. The chart shows a high speculative market valuation awaiting regulatory approval.
Market to book capitalization ratio for the market as a whole
DBV Technologies develops epicutaneous immunotherapy (skin patches) for the treatment of food allergies, primarily to peanuts. The company's main asset is its patented Viaskin technology. This chart illustrates why biotech companies with innovative platforms can have high market valuations even without profitability, reflecting their belief in future success.
Debts of the company, segment and market as a whole
DBVT - Company debts DBV Technologies S.A.
DBV Technologies, a biopharmaceutical company developing allergy patches, uses debt to finance clinical trials. This chart shows how the company raises capital to navigate the complex and costly stages of regulatory approval. In the biotech world, debt is the bridge between R&D and market entry.
Market segment debts - Pharma skin
DBV Technologies is developing epicutaneous immunotherapy, specifically a patch for the treatment of peanut allergies. Biopharmaceutical development, especially for children, requires lengthy and expensive clinical trials. This chart shows how the company is funding its innovative approach to allergy treatment while seeking approval.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio DBV Technologies S.A.
DBV Technologies, which develops treatments for food allergies, is in a capital-intensive research phase. This chart illustrates the company's reliance on external financing. High debt levels for a biopharma are a bet on the drug's future success, but also a huge risk if the product fails to receive regulatory approval and reach the market.
Market segment debt to market segment book capitalization - Pharma skin
DBV Technologies develops patches for the treatment of food allergies, particularly to peanuts. Biotech developments, especially in the late stages, require significant funding. The chart shows how the company's debt burden relates to the risks and overall market capitalization of the entire innovative pharmaceutical sector.
Debt to book value of all companies in the market
DBV Technologies (DBVT) develops innovative treatments for food allergies, such as peanut allergies. While in clinical trials, the company raises equity rather than borrows. This chart shows the overall debt burden of the economy, highlighting the funding gap between biotech and mature industries.
P/E of the company, segment and market as a whole
P/E - DBV Technologies S.A.
This chart for DBV Technologies, a biopharmaceutical company developing a peanut allergy patch, reflects the long road to regulatory approval. There is no price-to-earnings ratio (P/E). The company's entire valuation is a bet on its innovative product ultimately receiving FDA approval. The chart's dynamics depend entirely on news about clinical trials.
P/E of the market segment - Pharma skin
This chart illustrates the average P/E for biotech companies. For DBV Technologies, whose fate hinges on the regulator's decision, it serves as a backdrop. This metric reflects the overall level of hope in the sector. It helps understand the backdrop against which DBV is being valued, as it's betting on the success of a single, potentially revolutionary product.
P/E of the market as a whole
DBV Technologies is a French biopharmaceutical company developing the Viaskin platform for the treatment of food allergies, particularly to peanuts, using epicutaneous immunotherapy. This risk appetite chart helps understand how investors evaluate innovative approaches to allergy treatment and biotechnology in general.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company DBV Technologies S.A.
DBV Technologies is a French biopharmaceutical company developing epicutaneous immunotherapy (patches) for the treatment of food allergies, primarily to peanuts. This graph reflects expectations for the approval and commercial launch of its lead product. The valuation is highly sensitive to decisions by regulators, such as the FDA, and the results of clinical trials.
%20P%2FE%20DBV%20Technologies%20S.A.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-DBV-Technologies-S.A.&v=1772513542298 "Chart of the company's future (projected) P/E DBV Technologies S.A.")
Future (projected) P/E of the market segment - Pharma skin
DBV Technologies is developing epicutaneous immunotherapy, specifically a patch for the treatment of peanut allergies. The chart shows the company's expected future profitability relative to the pharmaceutical sector. It shows whether the market believes their innovative approach to allergy treatment will be commercially successful after receiving regulatory approval.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-skin&v=1772513542336 "Future (projected) P/E graph of the market segment - Pharma skin")
Future (projected) P/E of the market as a whole
DBV Technologies is developing an innovative patch for the treatment of food allergies. The company's success depends entirely on the results of clinical trials and regulatory approval. This chart of overall market expectations reflects the overall investment climate. Market optimism is helping biotech companies like DBV raise funds for research.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513542360 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit DBV Technologies S.A.
DBV Technologies is a French biopharmaceutical company developing the Viaskin patch for the treatment of food allergies, primarily to peanuts. The company is in the clinical trials stage. Its financial results are primarily based on R&D expenses. This chart shows the long and expensive path to potential approval and commercialization of the product.
Profit of companies in the market segment - Pharma skin
DBV Technologies is developing epicutaneous immunotherapy for the treatment of food allergies, particularly to peanuts. The company's financial results reflect the long and expensive clinical trials. This chart illustrates how the biotech sector is investing in innovative approaches, where current expenditures are betting on a future blockbuster that could transform the entire industry.
Overall market profit
DBV Technologies is a French biotech company developing a patch for the treatment of food allergies, specifically peanut allergies. Its success depends on regulatory approval and technology adoption. This schedule, reflecting market conditions, impacts its ability to raise capital, which is critical for companies on the cusp of commercialization.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company DBV Technologies S.A.
DBV Technologies is developing epicutaneous immunotherapy, specifically the Viaskin patch for the treatment of food allergies. This chart reflects analyst forecasts, which are entirely dependent on regulatory decisions, primarily FDA approval. A regulatory decision is a key event that could dramatically change the company's financial outlook.
%20profit%20of%20the%20company%20DBV%20Technologies%20S.A.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-DBV-Technologies-S.A.&v=1772513542545 "Graph of future (projected) profit of the company DBV Technologies S.A.")
Future (predicted) profit of companies in the market segment - Pharma skin
DBV Technologies is a French biopharmaceutical company developing the Viaskin patch for the treatment of food allergies, particularly to peanuts. This chart shows the revenue forecast for the dermatology and allergy pharmaceuticals. It reflects market expectations for new treatments, which is an important backdrop for assessing the commercial potential of DBV's innovative technology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-skin&v=1772513542629 "Graph of future (predicted) profits of companies in a market segment - Pharma skin")
Future (predicted) profit of the market as a whole
DBV Technologies is developing epicutaneous immunotherapy for the treatment of food allergies. Its future depends on successful clinical trials and regulatory approval. Macroeconomic trends, reflected in this chart, influence it indirectly through the overall availability of capital for the biotech sector and the solvency of healthcare systems.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513542668 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - DBV Technologies S.A.
DBV Technologies is a French clinical-stage biopharmaceutical company developing a patch for the treatment of food allergies, specifically peanut allergies. The company has no commercial revenue yet. This figure reflects the high expectations of investors, who are assessing the potential of its unique platform to change the lives of millions of allergy sufferers.
P/S market segment - Pharma skin
DBV Technologies is a French biopharmaceutical company developing the innovative Viaskin platform for the treatment of food allergies, such as peanut allergy, using epicutaneous immunotherapy (a skin patch). This chart shows the average valuation in the sector, helping to understand the market premium placed on the potential success of this unique technology.
P/S of the market as a whole
DBV Technologies is a French biopharmaceutical company developing epicutaneous immunotherapy, specifically for the treatment of peanut allergies in children. This innovative approach has significant market potential. This market valuation chart helps understand the premium investors are paying for the biotech's potentially revolutionary, yet risky, revenue.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company DBV Technologies S.A.
DBV Technologies is a clinical-stage biopharmaceutical company developing therapies for food allergies. With no commercial products, its value is determined by its future prospects. This chart reflects market expectations regarding the success of its key product and potential future sales if approved.
%20P%2FS%20DBV%20Technologies%20S.A.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-DBV-Technologies-S.A.&v=1772513542754 "The graph of the company's future (projected) P/S DBV Technologies S.A.")
Future (projected) P/S of the market segment - Pharma skin
DBV Technologies is developing epicutaneous immunotherapy (skin patches) for the treatment of food allergies, particularly to peanuts. This chart compares market expectations for its future revenue with other skin care companies. The valuation reflects investor expectations for approval of its innovative product, Viaskin Peanut.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20skin&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-skin&v=1772513542778 "Future (projected) P/S market segment graph - Pharma skin")
Future (projected) P/S of the market as a whole
DBV Technologies is developing an innovative treatment for food allergies using epicutaneous immunotherapy. The company's success depends on clinical trial results and regulatory approval. However, the overall market optimism reflected in the chart is increasing investor risk appetite and their willingness to fund biotech companies with breakthrough potential.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513542794 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales DBV Technologies S.A.
DBV Technologies is a biopharmaceutical company developing patches for the treatment of food allergies, primarily to peanuts. Being in the development stage, the company has no commercial sales yet, and its revenue, if any, comes from partnerships. This chart reflects the cash flows associated with clinical trials of its core technology.
Sales of companies in the market segment - Pharma skin
DBV Technologies is a French biopharmaceutical company developing an innovative treatment for food allergies using epicutaneous immunotherapy (patches). Currently, the company's primary revenue comes from collaborations with major partners. This chart reflects the state of the biotech market, where the potential of DBV's platform is attracting significant research investment.
Overall market sales
DBV Technologies is developing innovative patches for the treatment of food allergies. The company's success depends on regulatory approval and recognition from the medical community. While there's no direct correlation with economic cycles, the overall state of the economy, as shown by this chart, impacts healthcare budgets and their ability to cover new, expensive therapies.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company DBV Technologies S.A.
DBV Technologies is a French biopharmaceutical company developing epicutaneous immunotherapy (skin patches) for the treatment of food allergies, particularly to peanuts. The company's future depends on regulatory approval of its lead product, Viaskin Peanut. This chart shows analysts' assessments of the approval chances and commercial potential of this innovative therapy.
%20sales%20of%20the%20company%20DBV%20Technologies%20S.A.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-DBV-Technologies-S.A.&v=1772513542952 "Schedule of future (projected) sales of the company DBV Technologies S.A.")
Future (projected) sales of companies in the market segment - Pharma skin
DBV Technologies is a biopharmaceutical company developing an epicutaneous immunotherapy platform, primarily for the treatment of food allergies. This chart shows the outlook for the dermatological pharmaceutical sector, allowing one to assess how the potential success of its unique patch technology could impact the company's growth within the context of the overall industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-skin&v=1772513543005 "Schedule of future (projected) sales of companies in the market segment - Pharma skin")
Future (projected) sales of the market as a whole
DBV Technologies is developing epicutaneous immunotherapy for the treatment of food allergies. This schedule, reflecting the state of the healthcare system, is important to the company. Economic stability ensures funding for medical programs and the willingness of insurance companies to cover the costs of innovative treatments, which determines DBV Technologies' future commercial success.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513543055 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality DBV Technologies S.A.
DBV Technologies is developing a revolutionary patch for the treatment of food allergies, specifically peanut allergies. Currently, the company is fully focused on clinical trials and regulatory approval. This chart illustrates the significant investment in R&D required to create this potentially breakthrough medical product.
Market segment marginality - Pharma skin
DBV Technologies is developing the innovative Viaskin platform for the treatment of food allergies, particularly peanut allergies, using epicutaneous immunotherapy. While in clinical trials, the company is incurring significant R&D expenditures. This chart reflects the level of investment in their breakthrough technology, which, if successful, could yield a very high return on investment.
Market marginality as a whole
DBV Technologies is a French biotech company developing epicutaneous immunotherapy (a patch) for the treatment of food allergies. The overall profitability picture is irrelevant for them. Their fate depends entirely on the FDA's decision and approval of their product. It's a classic biotech story with a binary outcome, where years of research are at stake.
Employees in the company, segment and market as a whole
Number of employees in the company DBV Technologies S.A.
DBV Technologies is a French biotech company developing a patch for the treatment of food allergies. This graph shows the team of scientists and clinicians. The headcount dynamics are a barometer of the company's progress: growth during key trial stages and potential optimization in the event of regulatory delays.
Share of the company's employees DBV Technologies S.A. within the market segment - Pharma skin
DBV Technologies is developing an innovative epicutaneous immunotherapy (EPIT) platform for the treatment of food allergies. This chart shows the percentage of leading scientists in the fields of allergy and immunology that the company attracts. This demonstrates its scientific leadership and the scale of its efforts to create a non-invasive treatment for life-threatening conditions.
Number of employees in the market segment - Pharma skin
DBV Technologies is a French biopharmaceutical company developing epicutaneous immunotherapy (skin patches) for the treatment of food allergies. This chart illustrates employment in the pharmaceutical development sector. The dynamics of the number of researchers in this field reflect the efforts to find new, safer, and more convenient treatments for common diseases.
Number of employees in the market as a whole
DBV Technologies develops epicutaneous immunotherapy, primarily for the treatment of food allergies, such as peanut allergies. It is an innovative biopharmaceutical company with a staff of highly qualified scientists and specialists. This graph, which shows the overall labor market, highlights the biotech sector as a growth driver, creating jobs of the future in science and medicine.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company DBV Technologies S.A. (DBVT)
DBV Technologies S.A. is a biopharmaceutical company developing patches for food allergies. This chart shows that its value is determined by its intellectual property and future sales potential. A small team of scientists and managers is driving a multi-billion-dollar project forward, so the market capitalization per employee is extremely high. Investors are betting on their scientific breakthroughs.
%20of%20the%20company%20DBV%20Technologies%20S.A.%20(DBVT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-DBV-Technologies-S.A.-DBVT&v=1772513543356 "Chart of market capitalization per employee (in thousands of dollars) of the company DBV Technologies S.A. (DBVT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma skin
DBV Technologies is developing epicutaneous immunotherapy for the treatment of food allergies. The company's value lies in its patents and clinical trials. This chart measures the market valuation of this intellectual capital per team. Deviations from the mean may indicate investor confidence in the breakthrough potential of its developments.
%20by%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-skin&v=1772513543424 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma skin")
Market capitalization per employee (in thousands of dollars) for the overall market
DBV Technologies is developing innovative patches for the treatment of food allergies, representing a breakthrough in immunotherapy. This chart demonstrates the company's high market valuation per employee. This reflects market confidence in the potential of their unique technology, rather than current sales, which is typical for biopharmaceutical companies in the development stage.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513543490 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company DBV Technologies S.A. (DBVT)
DBV Technologies (DBVT) is a French biopharmaceutical company developing patches for the treatment of allergies (for example, to peanuts). Like other R&D companies, this chart shows the "cost of science." It measures how much the company spends (negative profit) per employee engaged in clinical trials and the development of its innovative Viaskin platform.
%20Chart%20DBV%20Technologies%20S.A.%20(DBVT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-DBV-Technologies-S.A.-DBVT&v=1772513543552 "Company Profit Per Employee (in thousands of dollars) Chart DBV Technologies S.A. (DBVT)")
Profit per employee (in thousands of dollars) in the market segment - Pharma skin
DBV Technologies, a French biotech company, is developing a patch (Viaskin) for the treatment of food allergies. This is a pioneering approach. Their business is complex clinical trials. This chart demonstrates the benchmark for biotech staff efficiency. It's important for assessing how effectively the DBV team is using investor capital to bring the product to market.
%20in%20the%20market%20segment%20-%20Pharma%20skin&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-skin&v=1772513543594 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma skin")
Profit per employee (in thousands of dollars) for the market as a whole
DBV Technologies is a French biopharmaceutical company known for developing the Viaskin patch for treating food allergies (such as peanuts). It's a classic biotech story: massive R&D investments per employee. This chart doesn't reflect current profits, but rather the cost of creating breakthrough intellectual property. The success of a single product can make this figure astronomical.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513543629 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee DBV Technologies S.A. (DBVT)
DBV Technologies is a biopharmaceutical company developing patches for the treatment of food allergies. This chart reflects its clinical status. The lack of significant revenue per employee is typical for companies whose products have not yet received regulatory approval. The entire team is focused on research, not commercial activities.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-DBV-Technologies-S.A.-DBVT&v=1772513543673 "Sales chart per company employee DBV Technologies S.A. (DBVT)")
Sales per employee in the market segment - Pharma skin
DBV Technologies (DBVT) is a French biotech company developing Viaskin, an epicutaneous patch for the treatment of food allergies (such as peanut allergies). This chart shows how much revenue (from partnerships) each employee (scientist) generates. It's an indicator of the productivity of their unique R&D platform compared to other biotechs in the field of allergy.
Sales per employee for the market as a whole
DBV Technologies is a French biotech company developing a patch for the treatment of food allergies. It's in the clinical stage, with minimal or no commercial revenue. This chart clearly illustrates the "cost" of R&D. While the company employs highly-paid scientists, the product isn't yet on the market, so the figure is close to zero, reflecting the stage of investment in research.
Short shares by company, segment and market as a whole
Shares shorted by company DBV Technologies S.A. (DBVT)
DBV Technologies is a French biotech company developing a patch (Viaskin) for the treatment of food allergies, specifically to peanuts. This chart shows bearish sentiment. Bears are shorting DBV due to a long history of failures: the FDA has denied the company's approval several times, citing insufficient efficacy and problems with the patch.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-DBV-Technologies-S.A.-DBVT&v=1772513543757 "Short Shares Chart for the Company DBV Technologies S.A. (DBVT)")
Shares shorted by market segment - Pharma skin
DBV Technologies (DBVT) is a French biopharmaceutical company developing epicutaneous immunotherapy (the Viaskin patch) for the treatment of food allergies, primarily to peanuts. This chart shows bets against the entire biotech sector. The rising price reflects deep investor skepticism about FDA approval, which the company has been denied several times.
Shares shorted by the overall market
DBV Technologies S.A. is a French biopharma company developing patches for the treatment of food allergies. This is a speculative story, dependent on regulatory decisions. This market pessimism chart is crucial. When fear dominates, investors are risk-averse. DBVT shares, lacking earnings, become prime candidates for selling.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator DBV Technologies S.A. (DBVT)
DBV Technologies is a French biotech that has been unsuccessfully trying to get FDA approval for its peanut allergy patch (Viaskin) for years. This chart measures fading hope. It shows when the stock is "oversold" on yet another rejection or "overbought" on speculation about a "last chance."
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-DBV-Technologies-S.A.-DBVT&v=1772513543877 "RSI 14 indicator chart for the company's stock DBV Technologies S.A. (DBVT)")
RSI 14 Market Segment - Pharma skin
DBV Technologies is a French biotech company developing the Viaskin platform—an epicutaneous patch for the treatment of food allergies, primarily peanut allergies. This chart measures the overall momentum of the allergy biotech sector. It helps separate DBV's volatility from the overall industry trend.
RSI 14 for the overall market
DBV Technologies, a biotech company, depends on this schedule. To fund expensive clinical trials, it requires a constant influx of capital. During periods of market euphoria, investors generously fund risky developments. During periods of panic, the "cash spigot" is turned off, and companies like DBVT are forced to survive.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast DBVT (DBV Technologies S.A.)
DBV Technologies is a French biotech company developing "epicutan" immunotherapy (Viaskin), a patch for the treatment of food allergies, primarily to peanuts. This chart shows the average 12-month analyst forecast. Their target price reflects the company's years-long battle for FDA approval.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-DBVT-DBV-Technologies-S.A.&v=1772513543999 "A chart showing analyst consensus forecasts for the expected stock price. DBVT (DBV Technologies S.A.)")
The difference between the consensus estimate and the actual stock price DBVT (DBV Technologies S.A.)
DBV Technologies is a French biotech company trying to treat peanut allergies with an innovative patch (Viaskin). This chart shows analysts' forecasts for the stock's upside and downside. It measures the gap between the price and forecast, reflecting their (skeptical) view of the patch's chances of regulatory approval.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-DBVT-DBV-Technologies-S.A.&v=1772513544058 "A chart showing the difference between the consensus forecast and the actual stock price. DBVT (DBV Technologies S.A.)")
Analyst consensus forecast for stock prices by market segment - Pharma skin
DBV Technologies is a French biotech company that has been trying for years to gain FDA approval for its Viaskin patch, which treats peanut allergies in children. This chart shows the overall expectations for the skin pharma sector, reflecting whether experts believe this long-suffering R&D program will succeed.
Analysts' consensus forecast for the overall market share price
DBV Technologies is a French biotech company developing an "epicutane" immunotherapy (Viaskin patch) for the treatment of food allergies, particularly peanut allergies, in children. This chart shows the overall risk appetite. For DBV, a company with a history of regulatory setbacks, overall market optimism is important for funding, but news from the FDA carries far more weight.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index DBV Technologies S.A.
DBV Technologies (DBVT) is a French biotech company whose fate is tied to a single product: Viaskin Peanut. It's an epicutaneous patch designed to treat peanut allergies in children. This chart charts their long and arduous battle with the FDA. Its progress depends entirely on their ability to secure regulatory approval for their innovative but complex product.
AKIMA Market Segment Index - Pharma skin
DBV Technologies (DBVT) is a French biotech focused on allergies; despite setbacks with the FDA, the company is a pioneer in the development of epicutaneous immunotherapy (Viaskin), a patch for treating peanut allergies. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this R&D rate (DBVT) differentiate it from the average pharma company?
The AKIM Index for the overall market
DBV Technologies is a French biotech company developing a patch (Viaskin) for the treatment of peanut allergies in children. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which is making a long journey toward FDA approval, compares to overall economic trends.
